drugset / Trial / NCT04664725
Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
NaSingle-groupOpen-labelBasic science
Summary
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
Timeline
- Start
- 2020-06-01
- Primary completion
- 2021-01
- Completion
- 2021-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | 150 mg | Oral |
| Subject | Repaglinide | Small molecule | 0.5 mg | Oral |
| Subject | Rezvilutamide | Small molecule | 240 mg | Oral |